Law360, New York (August 08, 2007, 12:00 AM ET) -- Novartis has lashed out at a bid by two plaintiffs in the Aredia and Zometa litigation over their bid to sanction the pharmaceutical company for refusing to remand their cases to state court, arguing that recent case law warrants that the court deny the plaintiffs’ remand request.
The drug giant said in court documents filed Monday that recent New Jersey case law permitting a jury to determine whether a pharmaceutical manufacturer committed fraud to the U.S. Food and Drug Administration and thus may be liable for...
Novartis Fights Bid For Sanctions Over Remand Issue
To view the full article, take a free trial now.
